5 Things to Know Before the Stock Market Opens

U.S. stock futures are advancing, with major indexes poised for a higher open, as the Senate passed a key procedural vote indicating a resolution to the government shutdown, alleviating market uncertainty. Concurrently, AI data center firm CoreWeave (CRWV) is anticipated to report revenue more than doubling to $1.3 billion, underscoring robust growth in the AI sector, with its shares up 5% premarket. Meanwhile, Metsera (MTSR) shares plummeted 15% following the announcement of its acquisition by Pfizer (PFE) for over $10 billion at $86.25 per share, a deal reportedly influenced by antitrust concerns regarding a competing bid from Novo Nordisk (NVO).

Analysis

U.S. stock futures are rising significantly, with Nasdaq up 1.5%, S&P 500 up 0.9%, and Dow up 0.4% premarket, as the Senate passed a key vote to end the six-week government shutdown. This resolution reduces market uncertainty, boosting Bitcoin to $106,000 and gold futures over 2%.

In corporate news, AI data center firm CoreWeave (CRWV) is expected to report revenue more than doubling to $1.3 billion, driven by major deals with Nvidia and Meta; its shares gained nearly 5% premarket. Conversely, Metsera (MTSR) shares plunged 15% premarket after Pfizer (PFE) agreed to acquire the weight-loss drug maker for $86.25 per share, a deal over $10 billion, following antitrust concerns preventing Novo Nordisk (NVO) from winning the bid.

President Trump's proposal for $2,000 "dividend" checks, funded by tariff revenues, introduces a new fiscal policy consideration. This initiative suggests potential for direct consumer stimulus, though its feasibility remains subject to political and legal processes.

Key Decisions for Investors

• Investors should monitor broader market indices for sustained positive momentum following the government shutdown resolution, indicating reduced systemic risk.
• Evaluate CoreWeave (CRWV) as a high-growth AI infrastructure play, considering its projected revenue doubling and strong premarket performance, while noting its current loss per share.
• Assess Pfizer's (PFE) strategic positioning in the weight-loss drug market post-Metsera acquisition, and consider the competitive landscape given Novo Nordisk's (NVO) regulatory challenges.
• Track developments on President Trump's tariff-funded dividend proposal, as potential consumer stimulus could influence sector-specific performance.